Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Skye Bioscience, Inc. - Common Stock (NQ:SKYE)

1.310 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 66,721
Open 1.350
Bid (Size) 1.310 (100)
Ask (Size) 1.320 (400)
Prev. Close 1.310
Today's Range 1.305 - 1.380
52wk Range 1.140 - 5.750
Shares Outstanding 417,247,333
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Skye Bioscience and Perrigo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire

Performance

YTD
-54.0%
-54.0%
1 Month
-17.1%
-17.1%
3 Month
-62.6%
-62.6%
6 Month
-33.8%
-33.8%
1 Year
-70.8%
-70.8%

More News

Read More
News headline image
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Earnings Scheduled For November 10, 2025 ↗
Via Benzinga
News headline image
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SKYE
From The DJS Law Group
Via Business Wire
News headline image
SKYE Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Skye Bioscience, Inc. Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights - SKYE
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights - SKYE
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Reminds Stockholders Spirit, Molina, Skye, and Perrigo of the Upcoming Deadlines and Urges Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Lost Money on Skye Bioscience, Inc. (SKYE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Lost Money on Skye Bioscience, Inc. (SKYE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Skye Bioscience to Participate in Upcoming Investment Conferences
Via Newsfile
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Skye Bioscience and Perrigo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit With the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
SKYE Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against Skye Bioscience, Inc.
From Robbins LLP
Via GlobeNewswire
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
Via The Motley Fool
News headline image
Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Insights Ahead: Skye Bioscience's Quarterly Earnings ↗
Via Benzinga
News headline image
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗
Via Investor's Business Daily
Topics Government
News headline image
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge ↗
Via Benzinga

Frequently Asked Questions

Is Skye Bioscience, Inc. - Common Stock publicly traded?
Yes, Skye Bioscience, Inc. - Common Stock is publicly traded.
What exchange does Skye Bioscience, Inc. - Common Stock trade on?
Skye Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Skye Bioscience, Inc. - Common Stock?
The ticker symbol for Skye Bioscience, Inc. - Common Stock is SKYE on the Nasdaq Stock Market
What is the current price of Skye Bioscience, Inc. - Common Stock?
The current price of Skye Bioscience, Inc. - Common Stock is 1.310
When was Skye Bioscience, Inc. - Common Stock last traded?
The last trade of Skye Bioscience, Inc. - Common Stock was at 11/28/25 01:00 PM ET
What is the market capitalization of Skye Bioscience, Inc. - Common Stock?
The market capitalization of Skye Bioscience, Inc. - Common Stock is 546.59M
How many shares of Skye Bioscience, Inc. - Common Stock are outstanding?
Skye Bioscience, Inc. - Common Stock has 547M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.